338 results on '"Sebti, Saïd M."'
Search Results
2. Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by allo-inactivation and ILC2-mediated tissue repair
3. Combined HMG-COA reductase and prenylation inhibition in treatment of CCM
4. Farnesyltransferase Inhibitors Potentiate the Antitumor Effect of Radiation on a Human Tumor Xenograft Expressing Activated HRAS
5. The Farnesyltransferase Inhibitor FTI-277 Suppresses the 24-kDa FGF2-Induced Radioresistance in HeLa Cells Expressing Wild-Type RAS
6. Supplementary Data from Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice
7. Supplementary Table 3 from RKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast Cancer
8. Data from A Novel Inhibitor of STAT3 Homodimerization Selectively Suppresses STAT3 Activity and Malignant Transformation
9. Supplementary Table 2 from RKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast Cancer
10. Supplementary Figure 2 from A Novel Inhibitor of STAT3 Homodimerization Selectively Suppresses STAT3 Activity and Malignant Transformation
11. Supplementary Figure 3 from RKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast Cancer
12. Supplementary Figure 1 from RKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast Cancer
13. Supplementary Figure 2 from RKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast Cancer
14. Supplementary Table 4 from RKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast Cancer
15. Data from RKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast Cancer
16. Supplementary Figure 1 from A Novel Inhibitor of STAT3 Homodimerization Selectively Suppresses STAT3 Activity and Malignant Transformation
17. Supplementary Table 1 from RKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast Cancer
18. Supplementary Figure 4 from RKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast Cancer
19. GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors
20. Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors
21. Peptidomimetic-Based Inhibitors of Farnesyltransferase
22. Protein Prenylation in Trypanosomatids : A New Piggy-Back Medicinal Chemistry Target for the Development of Agents Against Tropical Diseases
23. Farnesyltransferase and Geranylgeranyltransferase I Inhibitors as Novel Agents for Cancer and Cardiovascular Diseases
24. Prenyltransferase Inhibitors as Radiosensitizers
25. Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2
26. Selective Chemical Probe Inhibitor of Stat3, Identified through Structure-Based Virtual Screening, Induces Antitumor Activity
27. Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors
28. Non-peptidic substrate-mimetic inhibitors of Akt as potential anti-cancer agents
29. Activated Drosophila Ras1 is Selectively Suppressed by Isoprenyl Transferase Inhibitors
30. Metabolic Activation of Benzo(a)pyrene in SENCAR and BALB/c Mouse Embryo Cell Cultures
31. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT
32. Targeting protein prenylation for cancer therapy
33. Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer
34. Protein farnesyltransferase: Flexible docking studies on inhibitors using computational modeling
35. Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors
36. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity
37. Inhibition of Angiogenesis by Aβ Peptides
38. EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation
39. Loss of the cell cycle inhibitors p21Cip1 and p27Kip1 enhances tumorigenesis in knockout mouse models
40. Geranylgeranyltransferase-1 Inhibitors
41. Ras and RhoA suppress whereas RhoB enhances cytokine-induced transcription of nitric oxide synthase-2 in human normal liver AKN-1 cells and lung cancer A-549 cells
42. Simvastatin potentiates tumor necrosis factor α-mediated apoptosis of human vascular endothelial cells via the inhibition of the geranylgeranylation of RhoA
43. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies
44. Design of growth factor antagonists with antiangiogenic and antitumor properties
45. Inhibition of farnesyltransferase increases TGFβ type II receptor expression and enhances the responsiveness of human cancer cells to TGFβ
46. Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model
47. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts
48. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells
49. Design, synthesis, and evaluation of potent and selective benzoyleneurea-based inhibitors of protein geranylgeranyltransferase-I
50. Protein farnesylation: Implications for normal physiology, malignant transformation, and cancer therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.